HTG Molecular Diagnostics Statistics
Total Valuation
HTG Molecular Diagnostics has a market cap or net worth of 2.
| Market Cap | 2 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
HTG Molecular Diagnostics has 2.21 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 2.21M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +111.03% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | n/a |
| Float | 2.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 16.43.
| Current Ratio | 1.40 |
| Quick Ratio | 1.17 |
| Debt / Equity | 16.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.46 |
| Interest Coverage | -26.26 |
Financial Efficiency
Return on equity (ROE) is -343.21% and return on invested capital (ROIC) is -71.66%.
| Return on Equity (ROE) | -343.21% |
| Return on Assets (ROA) | -62.26% |
| Return on Capital (ROIC) | -71.66% |
| Revenue Per Employee | 115,079 |
| Profits Per Employee | -373,180 |
| Employee Count | 54 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 8.32 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.62% in the last 52 weeks. The beta is 2.69, so HTG Molecular Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 2.69 |
| 52-Week Price Change | -84.62% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 45.75 |
| Average Volume (20 Days) | 2,969 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.64 |
Income Statement
In the last 12 months, HTG Molecular Diagnostics had revenue of 6.21 million and -20.15 million in losses. Loss per share was -15.79.
| Revenue | 6.21M |
| Gross Profit | -4.92M |
| Operating Income | -19.59M |
| Pretax Income | -20.14M |
| Net Income | -20.15M |
| EBITDA | -19.10M |
| EBIT | -19.59M |
| Loss Per Share | -15.79 |
Balance Sheet
The company has 6.56 million in cash and 7.80 million in debt, giving a net cash position of -1.23 million or -0.56 per share.
| Cash & Cash Equivalents | 6.56M |
| Total Debt | 7.80M |
| Net Cash | -1.23M |
| Net Cash Per Share | -0.56 |
| Equity (Book Value) | 474,502 |
| Book Value Per Share | 0.21 |
| Working Capital | 2.63M |
Cash Flow
In the last 12 months, operating cash flow was -16.83 million and capital expenditures -20,867, giving a free cash flow of -16.85 million.
| Operating Cash Flow | -16.83M |
| Capital Expenditures | -20,867 |
| Free Cash Flow | -16.85M |
| FCF Per Share | -7.61 |
Margins
| Gross Margin | -79.14% |
| Operating Margin | -315.21% |
| Pretax Margin | -324.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HTG Molecular Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -106.10% |
| Shareholder Yield | -106.10% |
| Earnings Yield | -1,579,421,500.00% |
| FCF Yield | -761,107,164.42% |
Stock Splits
The last stock split was on December 21, 2022. It was a reverse split with a ratio of 0.0833333.
| Last Split Date | Dec 21, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.0833333 |
Scores
HTG Molecular Diagnostics has an Altman Z-Score of -34.95. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -34.95 |
| Piotroski F-Score | n/a |